Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IOVA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tumor Infiltrating Lymphocyte | Cervical Cancer | Phase 2 · NCT05686226 | Recruiting |
| Administration of Lymphodepletion | Metastatic Melanoma | N/A · NCT01701674 | Completed |
| Fludarabine Phosphate | Metastatic Melanoma | N/A · NCT01701674 | Completed |
| Cyclophosphamide | Metastatic Melanoma | N/A · NCT01701674 | Completed |
| Lifileucel (LN-144) | Metastatic Melanoma | Phase 3 · NCT05727904 | Recruiting |
| Modified Aldesleukin/Palivizumab Fusion Protein… | Unresectable Melanoma | Phase 1/2 · NCT06940739 | Recruiting |
| Tumor infiltrating lymphocytes (TIL) LN-145 | Metastatic Triple Negative Breast Cancer | Phase 2 · NCT04111510 | Completed |
| Autologous PD-1-knockout Tumor-infiltrating… | Unresectable Melanoma | Phase 1/2 · NCT05361174 | Recruiting |
| IOV-5001 | Advanced Solid Tumors | Phase 1/2 · NCT07743723 | Not yet recruiting |
| Autologous Tumor Infiltrating Lymphocytes LN-145 | Cutaneous Squamous Cell Carcinoma | Phase 2 · NCT07288073 | Recruiting |
| Autologous Tumor Infiltrating Lymphocytes… | Metastatic Melanoma | Phase 2 · NCT03645928 | Terminated |
| Nab-paclitaxel | Metastatic Melanoma | Phase 2 · NCT03645928 | Terminated |
| Autologous Tumor Infiltrating Lymphocytes… | Malignant Solid Neoplasm | Phase 2 · NCT03610490 | Terminated |
| Fludarabine | Cutaneous Squamous Cell Carcinoma | Phase 2 · NCT07288073 | Recruiting |
| Autologous Peripheral Blood Lymphocytes from… | Chronic Lymphocytic Leukemia | Phase 1 · NCT04155710 | Completed |
| Alpha-1-Antichymotrypsin | Malignant Pleural Effusion | Phase 1 · NCT07192900 | Recruiting |
Also used in these trials (approved or third-party drugs, not IOVA's own candidates): Pembrolizumab, Ipilimumab, Nivolumab, Nivolumab And Relatlimab-Rmbw, Paclitaxel, Pemetrexed Disodium, Aldesleukin, Carboplatin, Cisplatin, Durvalumab, Interleukin-2, Mesna.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IOVA holds $397.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $32.7M/quarter from operations, an estimated runway of 36.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 32 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IOVA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 33,366,587 | 7.21% | 2026-06-30 |
| MHR Fund Management, LLC | Institution (13F) | 28,967,103 | 6.26% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 21,695,003 | 4.69% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 18,396,706 | 3.98% | 2026-09-30 |
| Two Sigma Investments, LP | Institution (13F) | 14,964,996 | 3.23% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 12,279,882 | 2.65% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 10,452,242 | 2.26% | 2026-09-30 |
| Shaw D.E. & Co., Inc. | Institution (13F) | 9,163,428 | 1.98% | 2026-09-30 |
| Dimensional Fund Advisors LP | Institution (13F) | 6,238,693 | 1.35% | 2026-09-30 |
| Frederick G Vogt Interim CEO & General Counsel, Director · +93,756 options |
Insider | 604,144 | 0.13% | 2026-11-11 |
| Raj K. Puri Chief Regulatory Officer · +58,599 options |
Insider | 256,364 | 0.06% | 2026-09-08 |
| Daniel Gordon Kirby Chief Commercial Officer · +50,003 options |
Insider | 160,576 | 0.03% | 2026-11-10 |
Share count 462,655,151 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-11 filed 2026-11-13 |
Vogt Frederick G |
Option exercise (M) | 200,000 | $7.55 | 795,447 |
| 2026-11-11 filed 2026-11-13 |
Vogt Frederick G |
Tax withholding (F) | 191,303 | $8.09 | 604,144 |
| 2026-11-11 filed 2026-11-13 |
Vogt Frederick G |
Option exercise (M) | 200,000 | – | – |
| 2026-11-10 filed 2026-11-12 |
Kirby Daniel Gordon |
Option exercise (M) | 10,000 | – | 164,511 |
| 2026-11-10 filed 2026-11-12 |
Kirby Daniel Gordon |
Tax withholding (F) | 3,935 | $8.08 | 160,576 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IOVA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →